A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)

Inclusion Criteria: * Subject has histologically confirmed diagnosis of GBM. * Subject has failed or intolerant to radiotherapy. * Subjects has failed or intolerant to temozolomide therapy. * Subject has progressive disease with at least one measureable lesion on MRI. * Subject is at least 18 years of age. * Subject has a KPS ≥ 60. * Subject has adequate organ and marrow function. Exclusion Criteria: * Subject has received bevacizumab (Avastin). * Subjecting has any condition, including compromised pulmonary function, that would preclude the use of lomustine. * Subject is currently being treated with other investigational agents. * Subject has received other investigational therapy within the last 28 days. * Subject has received surgery within the last four weeks. * Subject is within 12 weeks of completion of radiation. * Subject has an active implantable or other electromagnetic device. * Subject has a metal implant, including a programmable shunt, in the head or neck that is incompatible with MRI. * Subject is known to be HIV positive. * Subject is pregnant, nursing or intends to become pregnant during the course of the study.